BRPI0915267A2 - Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição - Google Patents

Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição

Info

Publication number: BRPI0915267A2
Authority: BR; Brazil
Prior art keywords: pyrogen; disease; treating; compound; condition
Prior art date: 2008-11-14

Application number

BRPI0915267-9A

Other languages

English (en)

Inventor

Roger Tung

Original Assignee

Concert Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-14

Filing date

2009-11-13

Publication date

2015-08-18

2009-11-13 Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc

2015-08-18 Publication of BRPI0915267A2 publication Critical patent/BRPI0915267A2/pt

Links

150000001875 compounds Chemical class 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

BRPI0915267-9A 2008-11-14 2009-11-13 Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição BRPI0915267A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11498908P	2008-11-14	2008-11-14
PCT/US2009/006105 WO2010056344A1 (en)	2008-11-14	2009-11-13	Substituted dioxopiperidinyl phthalimide derivaties

Publications (1)

Publication Number	Publication Date
BRPI0915267A2 true BRPI0915267A2 (pt)	2015-08-18

Family

ID=42170217

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0915267-9A BRPI0915267A2 (pt)	2008-11-14	2009-11-13	Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição

Country Status (12)

Country	Link
EP (1)	EP2373165B1 (pt)
JP (1)	JP5647615B2 (pt)
KR (1)	KR101649332B1 (pt)
CN (1)	CN102245023B (pt)
AU (1)	AU2009314568B2 (pt)
BR (1)	BRPI0915267A2 (pt)
CA (1)	CA2743902C (pt)
EA (2)	EA020117B1 (pt)
ES (1)	ES2444433T3 (pt)
MX (1)	MX2011005112A (pt)
WO (1)	WO2010056344A1 (pt)
ZA (1)	ZA201104361B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8288414B2 (en)	2007-09-12	2012-10-16	Deuteria Pharmaceuticals, Inc.	Deuterium-enriched lenalidomide
US9045453B2 (en) *	2008-11-14	2015-06-02	Concert Pharmaceuticals, Inc.	Substituted dioxopiperidinyl phthalimide derivatives
WO2012068512A1 (en) *	2010-11-18	2012-05-24	Deuteria Pharmaceuticals Llc	3-deutero-pomalidomide
WO2012079075A1 (en)	2010-12-10	2012-06-14	Concert Pharmaceuticals, Inc.	Deuterated phthalimide derivatives
WO2012079022A1 (en) *	2010-12-10	2012-06-14	Concert Pharmaceuticals, Inc.	Substituted dioxopiperidinyl phthalimide derivatives
EP2699091B1 (en) *	2011-03-28	2017-06-21	DeuteRx, LLC	2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US20140221427A1 (en) *	2011-06-22	2014-08-07	Celgene Corporation	Isotopologues of pomalidomide
WO2013130849A1 (en)	2012-02-29	2013-09-06	Concert Pharmaceuticals, Inc.	Substituted dioxopiperidinyl phthalimide derivatives
EP2922838B1 (en) *	2012-10-22	2018-03-14	Concert Pharmaceuticals Inc.	Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
WO2014110322A2 (en) *	2013-01-11	2014-07-17	Concert Pharmaceuticals, Inc.	Substituted dioxopiperidinyl phthalimide derivatives
JP6359563B2 (ja) *	2013-01-14	2018-07-18	デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ，ＬＬＣ	３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
CA2941560A1 (en)	2013-03-14	2014-09-25	Deuterx, Llc	3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
LV14985B (lv)	2013-10-14	2015-06-20	Latvijas Organiskās Sintēzes Institūts	Lenalidom&imacr;da ieg&umacr;&scaron;anas process
JP6616934B2 (ja) *	2014-05-22	2019-12-04	株式会社資生堂	レナリドミドの光学分割方法
MY198587A (en) *	2014-09-14	2023-09-06	Avanir Pharmaceuticals Inc	Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
NZ731789A (en)	2014-10-30	2019-04-26	Kangpu Biopharmaceuticals Ltd	Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
US9809603B1 (en)	2015-08-18	2017-11-07	Deuterx, Llc	Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
RU2616976C1 (ru) *	2016-04-07	2017-04-19	Олег Ростиславович Михайлов	Кристаллическая β-модификация 3-(4-амино-1-оксо-1,3-дигидро-2Н-изоиндол-2-ил)-пиперидин-2,6-диона, способ её получения и фармацевтическая композиция на её основе
KR102368555B1 (ko)	2016-12-16	2022-02-28	강푸 바이오파마슈티칼즈 리미티드	조성물, 이의 적용 및 치료 방법
KR20210056397A (ko) *	2018-09-07	2021-05-18	메드샤인 디스커버리 아이엔씨.	삼환식 치환 피페리딘 디온계 화합물
JP7209897B2 (ja) *	2019-09-12	2023-01-20	メッドシャインディスカバリーインコーポレイテッド	Ｃｒｂｎタンパク質モジュレーターとしての二環式化合物
EP4122925A4 (en) *	2020-03-17	2024-04-17	Medshine Discovery Inc.	Proteolysis regulator and method for using same
CN115850686B (zh) *	2021-09-27	2026-01-30	广州谷森制药有限公司	新型氘代聚乙二醇脂质化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6281230B1 (en) *	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
DE122007000079I2 (de) *	1996-07-24	2010-08-12	Celgene Corp	Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
US7091353B2 (en)	2000-12-27	2006-08-15	Celgene Corporation	Isoindole-imide compounds, compositions, and uses thereof
DE602004018193D1 (de) *	2003-12-24	2009-01-15	Astrazeneca Ab	Pyrimidine mit tie2 (tek) aktivität
MX2007010037A (es) *	2005-02-18	2008-02-15	Novartis Vaccines & Diagnostic	Agentes antiangiogenicos con aldesleucina.
KR101380190B1 (ko) *	2005-07-29	2014-04-11	콘서트 파마슈티컬즈, 인크.	벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
JP2010517935A (ja) *	2007-02-09	2010-05-27	武田薬品工業株式会社	Ｐｐａｒ−ガンマのパーシャルアゴニストとしての縮合環化合物
US8288414B2 (en) *	2007-09-12	2012-10-16	Deuteria Pharmaceuticals, Inc.	Deuterium-enriched lenalidomide
US9045453B2 (en) *	2008-11-14	2015-06-02	Concert Pharmaceuticals, Inc.	Substituted dioxopiperidinyl phthalimide derivatives

2009
- 2009-11-13 JP JP2011536328A patent/JP5647615B2/ja not_active Expired - Fee Related
- 2009-11-13 EP EP09826438.5A patent/EP2373165B1/en active Active
- 2009-11-13 CN CN200980150592.2A patent/CN102245023B/zh not_active Expired - Fee Related
- 2009-11-13 EA EA201100750A patent/EA020117B1/ru not_active IP Right Cessation
- 2009-11-13 CA CA2743902A patent/CA2743902C/en not_active Expired - Fee Related
- 2009-11-13 KR KR1020117013575A patent/KR101649332B1/ko not_active Expired - Fee Related
- 2009-11-13 AU AU2009314568A patent/AU2009314568B2/en not_active Ceased
- 2009-11-13 WO PCT/US2009/006105 patent/WO2010056344A1/en not_active Ceased
- 2009-11-13 MX MX2011005112A patent/MX2011005112A/es active IP Right Grant
- 2009-11-13 BR BRPI0915267-9A patent/BRPI0915267A2/pt not_active Application Discontinuation
- 2009-11-13 ES ES09826438.5T patent/ES2444433T3/es active Active
- 2009-11-13 EA EA201391720A patent/EA201391720A1/ru unknown
2011
- 2011-06-10 ZA ZA2011/04361A patent/ZA201104361B/en unknown

Also Published As

Publication number	Publication date
EA201100750A1 (ru)	2011-12-30
CN102245023A (zh)	2011-11-16
AU2009314568A1 (en)	2010-05-20
CN102245023B (zh)	2015-05-13
EA201391720A1 (ru)	2014-04-30
WO2010056344A1 (en)	2010-05-20
KR101649332B1 (ko)	2016-08-18
EA020117B1 (ru)	2014-08-29
ZA201104361B (en)	2014-11-26
EP2373165A1 (en)	2011-10-12
KR20110086731A (ko)	2011-07-29
EP2373165A4 (en)	2012-06-20
JP5647615B2 (ja)	2015-01-07
JP2012508738A (ja)	2012-04-12
CA2743902C (en)	2016-09-20
EP2373165B1 (en)	2013-10-30
CA2743902A1 (en)	2010-05-20
ES2444433T3 (es)	2014-02-25
AU2009314568B2 (en)	2016-01-21
MX2011005112A (es)	2011-06-16

Similar Documents

Publication	Publication Date	Title
BRPI0915267A2 (pt)	2015-08-18	Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição
BRPI0815387A2 (pt)	2017-05-23	composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI0915382A2 (pt)	2017-06-27	composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BRPI0909180A2 (pt)	2016-08-09	composição farmacêutica, e, método de tratamento de uma doença autoimune
BR112012004333A2 (pt)	2015-09-08	composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0820474A2 (pt)	2017-05-23	método de tratamento de uma doença, uso de composto, e, composto
BRPI0909048A2 (pt)	2015-11-24	composição farmacêutica, e, método de tratamento de uma doença autoimune
BRPI0817525A2 (pt)	2014-11-18	Composto, composição farmacêutica, e, metódo de tratamento, controle ou prevenção de uma doença ou distúrbio.
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BR112014004181A2 (pt)	2017-06-13	composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
BRPI0908635A2 (pt)	2015-10-13	composto, composição farmacêutica e método de tratamento de câncer
BRPI0815708A2 (pt)	2014-09-30	Composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição.
BRPI0820568A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
BRPI0909179A2 (pt)	2015-08-25	Composição farmacêutica, e, método de tratamento de uma doença autoimune.
BRPI1008974A2 (pt)	2017-06-06	composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0912111A2 (pt)	2015-10-06	composto, composição farmacêutica, método para tratar, controlar ou prevenir uma doença ou distúrbio, e, forma de dosagem unitária única
BRPI0610514A2 (pt)	2016-11-16	composto, composição farmacêutica, e, método de tratamento de um distúrbio
BR112012028530A2 (pt)	2017-12-19	composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno
BRPI1004899A2 (pt)	2016-04-05	composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac
BRPI0906962A2 (pt)	2015-07-14	Composto, e, composição farmacêutica
BRPI0906556A2 (pt)	2015-07-07	Composto, e, composição farmacêutica
BRPI0921317A2 (pt)	2017-06-06	composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto

Legal Events

Date	Code	Title	Description
2015-08-25	B15I	Others concerning applications: loss of priority	Free format text: PERDA DA PRIORIDADE US 61/114,989 DE 14/11/2008 REIVINDICADA NO PCT/US2009/006105, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DE ENTRADA NA FASE NACIONAL SER DISTINTO DAQUELE QUE DEPOSITOU O PEDIDO ANTERIOR CUJA PRIORIDADE E REIVINDICADA E APRESENTOU COPIA DO CORRESPONDENTE DOCUMENTO DE CESSAO EM 11/08/2011, CONTUDO O PRAZO PARA A APRESENTACAO DA CESSAO DO DIREITO DE PRIORIDADE EXPIRAVA EM 12/05/202011 (60 DIAS APOS O DEPOSITO DE ENTRADA DA FASE NACIONAL DO BRASIL), CONFORME AS DISPOSICOES PREVISTAS
2015-11-24	B12F	Appeal: other appeals
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
2019-07-16	B07E	Notice of approval relating to section 229 industrial property law	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2020-01-14	B07A	Technical examination (opinion): publication of technical examination (opinion)
2020-07-14	B09B	Decision: refusal
2020-11-17	B09B	Decision: refusal	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL